Paintings by Peter Bodnar from 1958-1977 : catalog for the exhibition held March 27 through April 24, 1977, Illinois State Museum, Springfield, Illinois.

Mode of access: Internet.

University of Michigan Men's Basketball Team, 1978

Back Row: asst. coach Bill Frieder, coach John Orr, Joel Thompson, K. Michael Robinson, Len Lillard, co-captain Phil Hubbard, Tom Bergen, Paul Heuerman, Alan Hardy, asst. coach Jim Boyce, asst. coach Dan Fife

Front Row: Mngr. Mitchell Kaufman, Marty Bodnar, Mark Lozier, Cornel Williams, co-captain David Baxter, Mike McGee, John Johnson, Tom Staton, Mark Bodnar, ?, mngr. John Anderson

University of Michigan Men's Basketball Team, 1980

Back Row: jr. mngr. Robert Murphy, equip. mngr. Bob Hurst, trainer Dan Campbell, sr. mngr. Greg Ruggles, Marty Bodnar, Mike McGee, coach Bill Frieder, John Johnson, Joe James, Mark Bodnar, Dan Pelekoudas, asst. coach Mike Boyd, asst. coach Tom Kempf, grad. asst. Bud VanDeWege Jr.

Front Row: Dean Hopson, Ike Person, John Antonides, co-captain Thad Garner, co-captain Paul Heuerman, Tim McCormick, Leo Brown, Memi. C. Burton

University of Michigan Men's Basketball Team, 1981

Back Row: jr. mngr. Robert Murphy, equip. mngr. Bob Hurst, trainer Dan Campbell, sr. mngr. Greg Ruggles, Marty Bodnar, Mike McGee, coach Bill Frieder, John Johnson, Joe James, Mark Bodnar, Dan Pelekoudas, asst. coach Mike Boyd, asst. coach Tom Kempf, grad. asst. Bud VanDeWege Jr.

Front Row: Dean Hopson, Ike Person, John Antonides, co-captain Thad Garner, co-captain Paul Heuerman, Tim McCormick, Leo Brown, Memi. C. Burton

University of Michigan Men's Basketball Team, 1978

Back Row: Joel Thompson, K. Michael Robinson, Len Lillard, co-captain Phil Hubbard, Tom Bergen, Paul Heuerman, Alan Hardy

Middle Row: asst. coach Bill Frieder, head coach Johnny Orr, Marty Bodnar, Joh Lozier, Mark Bodnar, asst. coach Jim Boyce, asst. coach Dan Fife

Front Row: Mngr. Mitchell Kaufman, Cornel Williams, Thomas Staton, co-captain David Baxter, Mike McGee, John Johnson, ?, mngr. John Anderson

The WIL (Work Integrated Learning) report : a national scoping study [Final Report]

This report provides an account of the first large-scale scoping study of work integrated learning (WIL) in contemporary Australian higher education. The explicit aim of the project was to identify issues and map a broad and growing picture of WIL across Australia and to identify ways of improving the student learning experience in relation to WIL. The project was undertaken in response to high levels of interest in WIL, which is seen by universities both as a valid pedagogy and as a means to respond to demands by employers for work-ready graduates, and demands by students for employable knowledge and skills. Over a period of eight months of rapid data collection, 35 universities and almost 600 participants contributed to the project. Participants consistently reported the positive benefits of WIL and provided evidence of commitment and innovative practice in relation to enhancing student learning experiences. Participants provided evidence of strong partnerships between stakeholders and highlighted the importance of these relationships in facilitating effective learning outcomes for students. They also identified a range of issues and challenges that face the sector in growing WIL opportunities; these issues and challenges will shape the quality of WIL experiences. While the majority of comments focused on issues involved in ensuring quality placements, it was recognised that placements are just one way to ensure the integration of work with learning. Also, the WIL experience is highly contextualised and impacted by the expectations of students, employers, the professions, the university and government policy.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : the M77001 study group

Purpose: This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Patients and Methods: Patients were randomly assigned to six cycles of docetaxel 100 mg/m 2 every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression. Results: A total of 186 patients received at least one dose of the study drug. Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% v 34%; P = .0002), overall survival (median, 31.2 v 22.7 months; P = .0325), time to disease progression (median, 11.7 v 6.1 months; P = .0001), time to treatment failure (median, 9.8 v 5.3 months; P = .0001), and duration of response (median, 11.7 v 5.7 months; P = .009). There was little difference in the number and severity of adverse events between the arms. Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%). One patient in the combination arm experienced symptomatic heart failure (1%). Another patient experienced symptomatic heart failure 5 months after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 months. Conclusion: Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity. © 2005 by American Society of Clinical Oncology.